Agenda & Speakers Slides

Day 1: Agenda & Speakers Slides
Day 2: Agenda & Speaker Slides
Print Agenda (PDF)

Monday, November 18

12:30 – 1:00 PM 

Registration and Lunch

1:00 – 1:15 PM

Welcome and Opening Remarks
Amy Comstock Rick, President & CEO, Food and Drug Law Institute (FDLI)

1:15 – 2:00 PM 

During this session, we will level-set on essential definitions, such as cannabis, hemp, marijuana, CBD, THC, extracts, broad spectrum, and botanicals, and discuss the existence of other cannabinoids. Speakers will then broadly discuss how these terms are being used both correctly and incorrectly, and how they fit into the current exploding industry.

Alva C. Mather, Partner, McDermott Will & Emery
Megan L. Olsen, Assistant General Counsel, Council for Responsible Nutrition
Moderated by Bridget C.E. Dooling, Research Professor, George Washington University

2:00 – 3:00 PM 

The federal regulatory climate regarding cannabis-derived products is currently in a state of flux. This session will discuss the current status of cannabis regulation among various federal agencies, including the Drug Enforcement Administration (DEA), the United States Department of Agriculture (USDA), the Environmental Protection Agency (EPA), the U.S. Department of Justice (DOJ), and the Federal Trade Commission (FTC). The panelists will also explore how the Agriculture Improvement Act of 2018 (Farm Act) changed the federal regulation of hemp-containing products such as CBD, and the interplay between the Farm Act’s lack of federal preemption and state laws. 

Larry K. Houck, Attorney, Hyman, Phelps & McNamara, PC
Keith Matthews, Of Counsel, Wiley Rein LLP
Kristi L. Wolff, Partner, Kelley Drye & Warren LLP
Moderated by William A. GarvinShareholder, Buchanan Ingersoll & Rooney PC

3:00 – 3:15 PM 

Coffee and Networking Break

3:15 – 4:15 PM

Since passage of the Farm Act, what is the legal status of CBD-containing products and accessories sold as drugs, devices, foods, dietary supplements, vaping products, and/or cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act)? Are there solutions to the legal inconsistencies under the current statutory structure? Do recent FDA enforcement actions give us a glimpse into the future?

Brian J. Malkin, Counsel, Arent Fox LLP
Frederick A. Stearns, Partner, Keller and Heckman LLP
Christopher Van Gundy, Partner, Sheppard Mullin Richter & Hampton LLP
Moderated by Elizabeth Oestreich, Vice President, Regulatory Compliance, Greenleaf Health, Inc.

4:15 – 5:00 PM

The U.S. is currently a patchwork of state laws and regulations pertaining to medical and adult-use marijuana. State requirements with respect to hemp-derived products also vary widely due to the Farm Act’s lack of preemption.

Jonathan  A. Havens, Partner, Saul Ewing Arnstein & Lehr LLP
Steven N. Levine, Partner, Husch Blackwell LLP

5:00 – 5:30 PM

Keynote Address

Sharon Mayl, Senior Advisor for Policy, Office of the Commissioner, FDA

5:30 – 7:00 PM

Networking Reception
Sponsored by Arnold & Porter